Travere Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Okay. Good morning, and welcome to day 3 of the Barclays Global Healthcare Conference. My name is Carter Gould, Senior Biopharma Analyst here at Barclays. Pleased to welcome Travere Therapeutics to the stage. Travere's got a very active 2022 ahead of itself with a number of key regulatory updates and hopefully some new launches. And joining us on stage right now are CEO, Eric Dube; and then Peter Heerma, Chief Commercial Officer. Chris Cline from the IR team is also around here, too. So Eric and Peter, thank you very much for joining us today.
Thank you for hosting us.
Before we jump into Q&A, why don't we just pass it over to you first to maybe make some opening comments and give a little background of the company and we set up the conversation.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |